{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:16:40Z","timestamp":1793236600417,"version":"4.5.0"},"reference-count":41,"publisher":"Wiley","issue":"21","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Avelumab maintenance therapy was approved in Japan in February 2021 for the treatment of curatively unresectable urothelial carcinoma (UC) that has not progressed after prior chemotherapy based on results from the JAVELIN Bladder 100 phase 3 trial. We report the final analysis of postmarketing surveillance (PMS) data on the safety and effectiveness of avelumab maintenance in clinical practice in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective, multicenter, noninterventional PMS evaluated patients with curatively unresectable UC who received \u2265\u20091 dose of avelumab maintenance in Japan between February 2021 and December 2021. The observation period was \u2264\u200952\u2009weeks in all patients. The primary objective was to evaluate the safety of avelumab maintenance based on the occurrence of prespecified adverse drug reactions (ADRs). The secondary objective was to evaluate effectiveness, including time to treatment failure (TTF), time to next\u2010line treatment (TTNT), and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Data were collected from 453 patients at 213 sites (data cutoff: March 6, 2024). Median age was 73\u2009years, 90.3% had metastatic disease, and prior chemotherapy regimen was gemcitabine\u2009+\u2009cisplatin in 267 (58.9%), gemcitabine\u2009+\u2009carboplatin in 163 (36.0%), and others in 23 (5.1%). Any\u2010grade prespecified ADRs occurred in 144 patients (31.8%), including grade \u2265\u20093 in 35 patients (7.7%). The most common any\u2010grade prespecified ADRs were infusion reaction (11.7%) and thyroid dysfunction (7.3%). Median TTF was 4.6\u2009months (95% CI, 3.8\u20135.3\u2009months). Median TTNT was 9.9\u2009months (95% CI, 8.3\u2009months\u2014not estimable). OS rates at 6 and 12\u2009months were 89.2% (95% CI, 86.0%\u201391.8%) and 77.9% (95% CI, 73.7%\u201381.5%), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Final analysis of PMS provides the largest real\u2010world dataset of avelumab maintenance in Japan reported to date. Findings demonstrate the acceptable safety, tolerability, and effectiveness of avelumab maintenance, consistent with data from JAVELIN Bladder 100 and real\u2010world studies in other countries, and support its continued use in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>University Hospital Medical Information Network Clinical Trials Registry (UMIN\u2010CTR): UMIN 43435<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.71264","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:47:48Z","timestamp":1761817668000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real\u2010World Outcomes of Avelumab Maintenance Therapy in Patients With Curatively Unresectable Urothelial Carcinoma in Japan: Results From the Final Analysis of Postmarketing Surveillance"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1624-6676","authenticated-orcid":false,"given":"Eiji","family":"Kikuchi","sequence":"first","affiliation":[{"name":"Department of Urology St. Marianna University School of Medicine  Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Nagata","sequence":"additional","affiliation":[{"name":"Department of Urology Juntendo University Graduate School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taito","family":"Ito","sequence":"additional","affiliation":[{"name":"Medical Department Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA  Darmstadt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Sato","sequence":"additional","affiliation":[{"name":"Research and Development Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA  Darmstadt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mie","family":"Ogi","sequence":"additional","affiliation":[{"name":"Global Development Operations Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA  Darmstadt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Morita","sequence":"additional","affiliation":[{"name":"Global Patient Safety Japan Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA  Darmstadt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kajita","sequence":"additional","affiliation":[{"name":"Medical Department Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA  Darmstadt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nishiyama","sequence":"additional","affiliation":[{"name":"Department of Urology, Faculty of Medicine University of Tsukuba  Ibaraki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_2_11_3_1","unstructured":"National Cancer Center Japan \u201cProjected Cancer Statistics \u201d 2023 https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/short_pred_en.html."},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19199-z"},{"issue":"1","key":"e_1_2_11_5_1","article-title":"Epidemiology of Bladder Cancer","volume":"8","author":"Saginala K.","year":"2020","journal-title":"Medical Science"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.11.014"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.15014"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2016.08.016"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.10.013"},{"key":"e_1_2_11_10_1","unstructured":"National Cancer Institute \u201cSEER Cancer Stat Facts: Bladder Cancer \u201dhttps:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html."},{"key":"e_1_2_11_11_1","unstructured":"\u201cNCCN Clinical Practice Guidelines in Oncology: Bladder Cancer \u201d V1.2025 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf."},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.03.001"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.02.019"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.15362"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00152-2"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30230-0"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002788"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01792"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-021-02067-8"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2023.02.002"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2475734"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.15473"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.09.014"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmorw.2024.100068"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.06.008"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31090420"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102238"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e16621"},{"key":"e_1_2_11_29_1","volume-title":"Prescribing Information (Japan)","author":"Bavencio (Avelumab)","year":"2019"},{"key":"e_1_2_11_30_1","unstructured":"Japanese Urological Association \u201cSupplement to Clinical Practice Guidelines for Bladder Cancer (2019 Update) \u201d 2021 https:\/\/www.urol.or.jp\/lib\/files\/other\/guideline\/39_bladder_cancer_2019_rev2021_info.pdf."},{"key":"e_1_2_11_31_1","unstructured":"Ministry of Health Labor and Welfare of Japan \u201cMinisterial Ordinance on Standards for Conducting Post\u2010Marketing Surveillance and Testing of Pharmaceuticals \u201d (2020) https:\/\/elaws.e\u2010gov.go.jp\/document?lawid=416M60000100171_20220520_504M60000100084."},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104506"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71177"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2024.09.020"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100340"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.17547"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.400"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz060"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.52302"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.45596"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyae067"},{"key":"e_1_2_11_42_1","unstructured":"Astellas Pharma \u201cJapan's MHLW Approves PADCEV (Enfortumab Vedotin) for Advanced Urothelial Cancer \u201d (2021) https:\/\/www.astellas.com\/en\/news\/17206."}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71264","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.71264","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71264","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:34:22Z","timestamp":1777530862000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":41,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1002\/cam4.71264"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71264","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"2024-12-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71264"}}